CD284 (TLR4) polyclonal, anti-human, mouse, rat, sheep, bovine
€378.00
In stock
SKU
251111
Catalog Nr.: 251111
Size: 0.1 mg
Isotype: Rabbit Ig
Applications: E, WB, IHC
Size: 0.1 mg
Isotype: Rabbit Ig
Applications: E, WB, IHC
Protein Family: Cellular Antigens, Receptors and Channels
Pathway and Disease: Immune System, Infectious Diseases, Signaling Molecules and Interaction
Description:
Toll-like receptor family (TLR) has a fundamental role in pathogen recognition and activation of innate immunity. TLRs are highly conserved from Drosophila to humans and share structural and functional similarities. TLRs recognize pathogen-associated molecular patterns (PAMP) that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity. Toll-like receptor 4 (TLR4) cooperates with LY96 and CD14 to mediate the innate immune response to bacterial lipopolysaccharide (LPS). TLR4 acts via MYD88, TIRAP and TRAF6 to lead to NFkB activation, cytokine secretion and inflammatory response. TLR4 is highly expressed in placenta, spleen and peripheral blood leukocytes. Genetic variation in TLR4 is associated with age-related macular degeneration 10 (ARMD10), an irreversible vision loss.
Alternate Names: Toll-like receptor 4, hToll, CD284, TLR4
Application Notes: E: 1:500-1:1,000; WB: 1:200-1:500; IHC: 1:100-1:500
Accession No.: O00206
Antigen: KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of rat TLR4.
Format: Each vial contains 0.1 mg IgG in 0.1 ml (1 mg/ml) of PBS pH7.4, 25% glycerol, 1 mg/ml BSA with 0.09% sodium azide. Antibody was purified by Protein-A affinity chromatography.
Storage:
Store at -20°C. Minimize freeze-thaw cycles. Product is guaranteed one year from the date of shipment.
Product Citations:
[1] Luttgenau J et al. 2016. Reproduction. 151(4): 391-9. PMID 26762400.
[2] Kulikova GV et al. 2016. Bull Exp Biol Med. 160(5): 718-21. PMID 27021078.
[3] Garcia PV et al. 2016. BMC Cancer. 16:42. PMID 27389279.
[4] Garcia PV. et al. 2015. Int J Clin Exp Pathol. 8(5): 4427-43. PMID 26191134
[5] Stopiglia R et al. 2015. J Cancer Therapy. 6: 129-140.
[6] Kusumawardani B et al. 2013. Dental Journal, Majalah Kedokteran Gigi. 45(3).
Pathway and Disease: Immune System, Infectious Diseases, Signaling Molecules and Interaction
Description:
Toll-like receptor family (TLR) has a fundamental role in pathogen recognition and activation of innate immunity. TLRs are highly conserved from Drosophila to humans and share structural and functional similarities. TLRs recognize pathogen-associated molecular patterns (PAMP) that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity. Toll-like receptor 4 (TLR4) cooperates with LY96 and CD14 to mediate the innate immune response to bacterial lipopolysaccharide (LPS). TLR4 acts via MYD88, TIRAP and TRAF6 to lead to NFkB activation, cytokine secretion and inflammatory response. TLR4 is highly expressed in placenta, spleen and peripheral blood leukocytes. Genetic variation in TLR4 is associated with age-related macular degeneration 10 (ARMD10), an irreversible vision loss.
Alternate Names: Toll-like receptor 4, hToll, CD284, TLR4
Application Notes: E: 1:500-1:1,000; WB: 1:200-1:500; IHC: 1:100-1:500
Accession No.: O00206
Antigen: KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of rat TLR4.
Format: Each vial contains 0.1 mg IgG in 0.1 ml (1 mg/ml) of PBS pH7.4, 25% glycerol, 1 mg/ml BSA with 0.09% sodium azide. Antibody was purified by Protein-A affinity chromatography.
Storage:
Store at -20°C. Minimize freeze-thaw cycles. Product is guaranteed one year from the date of shipment.
Product Citations:
[1] Luttgenau J et al. 2016. Reproduction. 151(4): 391-9. PMID 26762400.
[2] Kulikova GV et al. 2016. Bull Exp Biol Med. 160(5): 718-21. PMID 27021078.
[3] Garcia PV et al. 2016. BMC Cancer. 16:42. PMID 27389279.
[4] Garcia PV. et al. 2015. Int J Clin Exp Pathol. 8(5): 4427-43. PMID 26191134
[5] Stopiglia R et al. 2015. J Cancer Therapy. 6: 129-140.
[6] Kusumawardani B et al. 2013. Dental Journal, Majalah Kedokteran Gigi. 45(3).
| Is Featured? | No |
|---|
Write Your Own Review